Article Dans Une Revue Haemophilia Année : 2020

Cost‐effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti‐FVIII inhibitors in France

Domaines

Biotechnologies

Dates et versions

hal-04916973 , version 1 (28-01-2025)

Identifiants

Citer

Benoît Polack, Marc Trossaërt, Mathias Cousin, Sandrine Baffert, Alexandra Pruvot, et al.. Cost‐effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti‐FVIII inhibitors in France. Haemophilia, 2020, 27 (1), ⟨10.1111/hae.14129⟩. ⟨hal-04916973⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More